Last week, we discussed the growing use of biosimilar types of insulin and smart insulin pens, which should be available in the next few years in Quebec. This week, we look at what continuous glucose monitoring (CGM) systems, insulin pumps and other tools have in store for us. Continuous glucose monitoring systems The Freestyle Libre … Read more
There has been a lot going on these past few years in terms of promising new treatments and technology and the coverage provided to people with type 1 diabetes (T1D) by the Régie de l’assurance maladie du Québec (RAMQ). Biosimilar insulin Biosimilar insulin is a similar copy of an existing biological type of insulin (the … Read more
The first ever drug to prevent and delay the onset of type 1 diabetes (T1D) in patients at a higher risk of developing it in the short term—a new injectable medication with an unusual name, Teplizumab—is about to be approved and made available on the U.S. market. On May 27, 2021, the U.S. Food and Drug … Read more